GO
Loading...

AstraZeneca PLC

More

  • LONDON, March 5- AbbVie's $21 billion deal to buy Pharmacyclics shows big pharma's hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine. AbbVie's planned purchase of Pharmacyclics is the largest global pharmaceutical deal of 2015 to date and takes M&A activity in the sector...

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • UPDATE 1-Actavis' superbug antibiotic gets U.S. approval Wednesday, 25 Feb 2015 | 7:50 PM ET

    Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • Feb 5- Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira shares soared 35 percent to nearly $88 on Thursday, while Pfizer was up 2.7 percent at $32.93.

  • Feb 5- Drugmaker Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectible drugs and biosimilars, or copies of biotech drugs. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira soared 35 percent to near $88 before the bell Thursday, while Pfizer was up 3.6...

  • *Deal builds on last year's purchase of Almirall drugs. LONDON, Feb 5- AstraZeneca has agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial $600 million as it seeks external deals to ensure growth. AstraZeneca will also pay another $100 million, after Actavis agreed to a number of changes to ongoing agreements...

  • LONDON, Feb 5- AstraZeneca said on Thursday it had agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial payment of $600 million as it seeks external deals to ensure growth. The British group, which saw off a $118 billion bid by Pfizer last year, said its sales in the fourth quarter fell 2 percent to $6.68 billion,...

  • Stocks close up sharply, boosted by Greece and oil Monday, 2 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed sharply higher on encouraging news from the Eurozone and stronger oil prices.

  • Feb 2- Ardelyx Inc said chronic kidney disease patients treated with its kidney drug experienced higher-than-expected levels of diarrhea in a mid-stage study. The drug, Tenapanor, being co-developed with AstraZeneca PLC, however, met the main goal of "significantly" reducing phosphate levels in patients who were on dialysis. Ardelyx licensed the drug to...

  • Feb 2- Ardelyx Inc said its experimental drug "significantly" decreased phosphate levels in chronic kidney disease patients who were on dialysis. Ardelyx licensed the drug to AstraZeneca in October 2012. Under the terms of the agreement, AstraZeneca handles the development costs for tenapanor, while Ardelyx runs the trials.

  • Feb 2- Ardelyx Inc said its experimental drug significantly decreased phosphate levels in chronic kidney disease patients who were on dialysis.

  • *Sanofi struggling to find new CEO in narrow field. PARIS, Jan 30- Barring a last-minute breakthrough, drugs firm Sanofi's Chairman Serge Weinberg may have to acknowledge in his results presentation next week that the hunt for a new chief executive is not going well. Paris- schooled Olivier Bohuon, chief executive of British medical devices maker Smith& Nephew,...

  • *AstraZeneca working with academic groups and Thermo Fisher. LONDON, Jan 29- AstraZeneca said on Thursday it had struck four research agreements in the hot area of genome editing as it bets on a new "genetic scissors" technology to deliver better and more precise drugs for a range of diseases. The collaborations with Britain's Wellcome Trust Sanger Institute, the...

  • Jan 27- Pfizer Inc reported stronger-than-expected quarterly sales due to cost cuts and demand for its vaccines and cancer drugs, but the company forecast 2015 earnings below Wall Street expectations, citing patent expirations and the stronger dollar. Excluding special items, Pfizer earned 54 cents per share. Pfizer forecast 2015 earnings of $2.00 to $2.10...

  • Jan 26- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug. Nexium raked in about $1.9 billion in global sales in the first half of 2014, according to AstraZeneca's latest earnings statement.

  • Davos: Why M&A won't go away Friday, 23 Jan 2015 | 2:40 AM ET

    Activist shareholders in 2014 helped the mergers and acquisitions landscape return to the pre-crisis days of 2007 – and they'll continue to make news.

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • Elder statesman of Sweden's Wallenberg dynasty dies Monday, 19 Jan 2015 | 7:57 AM ET

    STOCKHOLM, Jan 19- Peter Wallenberg, the elder statesman of Sweden's business dynasty, died on Monday, the family investment foundation said. Peter Wallenberg, who was 88, had been chairman of the family's listed investment vehicle Investor from 1982 to 1997. More recently he had stepped back from day-to-day business activities. Peter Wallenberg has passed...

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....